Bruker MALDI Biotyper® System
The Bruker MALDI Biotyper® System is used for rapid microbial identification.
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Great results, fast and dependable
Used to identify bacteria and fungi found during research projects.
The Maldi Tof makes identifying organisms easy as well as cost-effective due to the fact that molecular techniques are not always needed for identification.
Review Date: 25 Feb 2024 | Beckman Coulter Diagnostics
Wonderful experience
Species identidification
Maldi-tof is an easiest way to identify all bacterial species in a very short time. You just need basic preparation and job is done. All in all 10-15 min.
Review Date: 28 Mar 2023 | Beckman Coulter Diagnostics
Mass spec is the ultimate in identification
Identify bacterial organisms
Brukers Mass Spec analyzers are the ultimate machines for identification. I can identify yeast, fungus, anaerobes, and mycobacterium. What takes normally 24-72 hours, now can be identified in less than 20 minutes from an isolated colony. The ease of use, little maintenance, and service dial-in capabilities is just icing on the cake. Antimicrobial stewards love this machine as it aides in their choice of treatment much more effectively than anything in the past.
Review Date: 30 May 2018 | Beckman Coulter Diagnostics
The Bruker MALDI Biotyper® System uses MALDI-TOF technology which is highly accurate and applicable to a wide range of microorganisms.
This cost-effective system is much faster than traditional methods and provides the ideal complement to the MicroScan WalkAway plus System.
Brochures
Your laboratory's pathway to accurate antibiotic prescription
Antibiotic resistance is one of the greatest threats to global public health—projected to cause 10 million deaths annually by 2050. The ability to prescribe the right antibiotic at the right time has never been more critical.
In this brochure, find out how Beckman Coulter’s DxM Trio delivers the precision and speed your clinical laboratory needs to support effective antibiotic stewardship.
Key takeaways
- Real-time detection
Detect emerging resistance confidently with MicroScan® panels—ensuring accurate and timely results. - Rapid organism ID
Identify pathogens in minutes using Bruker’s MALDI Biotyper® sirius System—the most comprehensive organism library on the market. - Direct ID from positive blood cultures
Save time and improve outcomes with Bruker’s MBT Sepsityper® for faster turnaround. - Workflow efficiency
Intuitive interface and visual cues on the DxM MicroScan WalkAway system help streamline lab operations.
With antibiotic development slowing and resistance accelerating, your laboratory plays a pivotal role. Download the brochure to learn how to empower your team to identify threats early, guide appropriate therapy, and optimize care—safely, efficiently, and reliably.
Revolutionize infection control with infrared spectroscopy
Looking to enhance your infection control protocols and microbial surveillance with high-throughput precision?
The Bruker IR Biotyper® harnesses the power of Fourier Transform Infrared (FT-IR) spectroscopy to deliver rapid, reproducible strain typing of microorganisms—helping laboratory professionals streamline outbreak detection, hygiene monitoring, and epidemiological investigations.
What you’ll learn:
- How the IR Biotyper supports real-time transmission route tracking
- Overview of the fast, user-friendly sample-to-result workflow
- Performance details of the FT-IR spectrometer and accessory kits
- Use cases for strain classification, pattern analysis, and surveillance
Ideal for:
Clinical microbiologists, infection control specialists, and laboratory scientists involved in microbial typing and outbreak investigations.
Invisible enemies: Revolutionizing infection control and microbial identification
June 13, 2025 - 16:00 BST / 17:00 CEST / 11:00 EDT / 08:00 PDT
Detect invisible enemies with speed and precision to enhance infection control in your healthcare institution.
Infection control prevents or stops the spread of infections in healthcare settings. The Bruker IR Biotyper, using Fourier Transform Infrared (FT-IR) spectroscopy, can differentiate microorganisms on the strain level, supporting infection control practices and timely data results.
Join Dr. Philip Jessmon as he demonstrates the value of the IR Biotyper technology along with the complementary MALDI Biotyper technology for rapid microorganism identification.
Key learning objectives:
- Summarize the impact on hospital hygiene for receiving rapid microbial results
- Identify how Fourier Transform-Infrared (FT-IR) spectroscopy technology is used for outbreak identification
- Assess how an FT-IR solution impacts infection control and prevention
Who should attend?
- Clinical microbiologists
- Lab directors, managers, supervisors and technicians
- Hospital administrators
- Epidemiologists
- Infection prevention specialists
- Infection control nurses
- Infection preventionists
- Infectious disease doctors
- Research or clinical PhDs
- Certified infection control (CIC) credentialed people
- Public health laboratory technicians
- Directors/Managers/Supervisors
- AMR stewardship committee members
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Managing antimicrobial resistance: A healthcare system's approach to antimicrobial detection and stewardship
Over the past five years, healthcare systems have faced a troubling rise in Gram-negative multidrug-resistant organisms (MDROs), contributing to increased patient morbidity and mortality. At the forefront of this surge are NDM-CREs (New Delhi metallo-β-lactamase-producing carbapenem-resistant Enterobacterales), which have skyrocketed by 460% between 2019 and 2023, according to a recent report from the Centers for Disease Control and Prevention (CDC)1. Another report by the European Centre for Disease Control (ECDC) showed a 57% increase in bloodstream infections caused by carbapenem resistant bacteria in the same time period2.
These alarming trends underscore the urgent need for robust screening protocols and precise antibiotic susceptibility testing, especially for high-risk patient populations.
Join our group of industry experts for an insightful case-based webinar exploring the complex patient journey of a 76-year-old woman residing in a nursing home. Her story begins with a fall leading to an emergency room visit where she is found to have a hip fracture. She is admitted and has an uneventful surgical repair the next day but develops urosepsis during her post-op recovery.
This case highlights the heightened vulnerability of elderly patients to MDROs, particularly CREs. Through this patient’s journey, the speakers will examine the critical role of infection prevention protocols and the value of accurate diagnostic and antibiotic susceptibility testing in guiding effective treatment as they are applied throughout a healthcare system.
The session will also incorporate the latest IDSA guidelines for managing complicated urinary tract infections, including urosepsis, offering practical insights for clinicians, microbiologists, and infection control professionals.
Key learning objectives:
- Describe how rapid PCR screening plays a critical role in enhancing infection control protocols to help minimize transmission and support timely patient management.
- Explain how rapid AST results support optimal antimicrobial therapy decision-making to help improve patient outcomes and combat resistance.
- Outline the latest IDSA guidelines for complicated urinary tract infections.
- Discuss the impact of antimicrobial resistance and diagnostic stewardship in real-world settings.
Who should attend?
Clinical microbiology lab directors/supervisors/managers, microbiologists, microbiologist lab technicians, infectious disease specialists, infectious disease pharmacists, clinical microbiology lab executives, antibiotic stewardship committee members, infection preventionists
Accreditation statement
SelectScience® is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program.
References:
1. CDC Report Finds Sharp Rise in Dangerous Drug-Resistant Bacteria | CDC Newsroom
2. Antimicrobial resistance in the EU/EEA (EARS-Net) - Annual Epidemiological Report 2023
MIC vs. Resistance mechanisms: What is needed to treat MDRO gram negative infections?
Phenotypic antimicrobial susceptibility testing is the gold standard test for treatment decisions, but emerging antimicrobial resistance and new antimicrobials for Gram-negative bacterial infections are challenging the conventional wisdom that a minimum inhibitory concentration (MIC) is all that is needed. Asking the question, "How can we meet evolving diagnostic needs?", we hear from three key microbiology and infectious disease experts: Prof. Navaneeth Narayanan, Rutgers University Ernest Mario School of Pharmacy, Prof. Amy Mathers, University of Virginia, School of Medicine, and Dr. April Abbott, Deaconess Health System, in this educational webinar.
Key learning objectives
- Discover the new drugs available for treating MDRO Gram-negative infections
- Understand the challenges and opportunities associated with MDRO Gram-negative diagnostics
Who should attend?
- Clinical microbiology lab directors/supervisors/managers
- Microbiologists
- Microbiologist lab technicians
- Infectious disease specialists
- Infectious disease pharmacists
- Clinical microbiology lab executives
- Antibiotic stewardship committee members
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
Bruker announces FDA clearance of Claims 7 and 8 for the MALDI Biotyper CA System
FDA clearance of MBT FAST™ Shuttle US IVD and MBT Compass HT CA software improves workflow efficiency and accelerates data processing and FDA approval of expanded reference library increases coverage to 549 validated microbial species
